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MMP-14We previously showed that lumican regulates MMP-14 expression. The aim of this study was to com-
pare the effect of lumican and decorin on MMP-14 activity. In contrast to decorin, the glycosylated
form of lumican was able to signiﬁcantly decrease MMP-14 activity in B16F1 melanoma cells. Our
results suggest that a direct interaction occurs between lumican and MMP-14. Lumican behaves
as a competitive inhibitor which leads to a complete blocking of the activity of MMP-14. It binds
to the catalytic domain of MMP-14 with moderate afﬁnity (KD  275 nM). Lumican may protect col-
lagen against MMP-14 proteolysis, thus inﬂuencing cell–matrix interaction in tumor progression.
Structured summary of protein interactions:
MMP-14 binds to Lumican by surface plasmon resonance (View interaction)
MMP-14 cleaves Lumican by enzymatic study (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction collagen assembly [6] and in the control of cell migration [7]. ApartThe small leucine-rich proteoglycans (SLRP) family consists of
17 extracellular proteins, which are structurally and functionally
related. They contribute to extracellular matrix (ECM) assembly
and organization through protein:protein and/or protein:carbohy-
drate interactions [1]. Lumican is composed of a 38 kDa core pro-
tein, which can be found, according to tissue, in different forms,
namely glycoprotein or proteoglycan, due to the glycosylation pro-
ﬁle [2]. The keratan sulfate – containing proteoglycan form of lumi-
can is mainly found in corneal stroma [3], whereas the
glycoprotein form of lumican is detected in other tissues, like der-
mis [2]. Non-glycosylated lumican core protein can be also
expressed in physiological conditions, like in lung ﬁbroblasts [4].
Lumican, like other members of this family, possesses 11 leucine
rich repeats (LRR) [5]. LRR motifs participate in the process offrom their structural function in the control of collagen ﬁbril
assembly, SLRPs, particularly lumican and decorin, can regulate
tumor cell behavior [8]. Lumican was shown to inhibit melanoma
progression [9] and metastasis [10] in vivo. Decorin, another mem-
ber of SLRP family, was also shown to be a powerful modulator of
cell growth affecting several key processes, including matrix
assembly, growth factor binding, and receptor tyrosine kinase
activity [11,12]. Additionally, decorin is able to inhibit melanoma
cell migration by intracellular acidiﬁcation [13].
The modulation of matrix function is also assessed by matrix
metalloproteinases (MMPs). They are zinc-dependent endopeptid-
ases which can be subgrouped into extracellular and membrane-
type MMPs. The latter, comprising six members, are characterized
by a C-terminal transmembrane domain that allows them to be
anchored in the cell membrane [14]. The organization of the differ-
ent domains of most MMP family members is conserved: a N-ter-
minal signal peptide, a propeptide, a catalytic domain, a hinge
region, and a hemopexin-like domain [15].
MMPs are known to play key roles in normal and pathologi-
cal conditions involving remodeling and turnover of the ECM,
such as embryonic development, wound healing, angiogenesis,
and inﬂuence numerous pathologies like arthritis, cardiovascular
diseases and cancer [16]. MMPs are overexpressed in various
4320 K. Pietraszek et al. / FEBS Letters 588 (2014) 4319–4324human malignancies and have been thought to contribute to
tumor invasion and metastasis by degrading ECM components
[17]. MMP-14, in particular, was reported to be closely associ-
ated with tumor invasion and metastasis. It was shown that
overexpression of MMP-14 promotes selective invasion and
growth of malignant melanoma in vivo [18]. MMP-14 itself can
degrade ECM macromolecules directly and/or by activating other
MMPs, like pro-MMP-2 thus enhancing cell migration [19]. Some
members of MMP family are able to cleave the SLRPs. Particu-
larly, MMP-14 can cleave human decorin [20] and lumican core
protein [21].
Inversely, SLRPs are able to regulate MMP expression and
activity. In an endothelial-like EA.hy926 cell line, induction of
decorin expression transitory increased the expression of
MMP-14 [22]. On the other hand, exogenous decorin decreased
MMP-2 and MMP-9 expression and enzymatic activity in HeLa
cells [23]. Lumican was shown to down-regulate MMP-14 expres-
sion in endothelial cells [24] and mesenchymal stem cells [25].
Considering the important impact of MMP-14 in tumor cell
migration and malignant progression (for review see [26]) and
the antimigratory and antitumoral role of lumican, we focused
on the direct interaction between these two macromolecules
according to the lumican glycosylation status. Moreover, the
current study compares the effects of lumican and decorin on
MMP-14 activity and characterizes lumican as a new inhibitor
of MMP-14.2. Materials and methods
2.1. Materials
Recombinant human pro-MMP-14 (catalytic domain, amino
acids 89-265) was obtained from Merck Millipore (Nottingham,
UK). Prior to the enzymatic activity assays, pro-MMP-14 was incu-
bated with APMA (AnaSpec, San Jose, USA) to convert the enzyme
in the active form. Recombinant human lumican (57 kDa) and its
core protein (37 kDa) were produced as previously described
[9,27]. Recombinant human decorin was obtained from EMP Gene-
tech (Ingolstadt, Germany). Rat tail tendon type I collagen was pre-
pared by acetic acid extraction, NaCl precipitation as described
[28]. Chondroitinase ABC (EC Number 4.2.2.4) was obtained from
Seikagaku Corporation (Tokyo, Japan) and mouse monoclonal
anti-decorin antibody from R&D Systems (Lille, France). Rabbit
polyclonal anti-lumican antibody was produced as previously
described [7]. The corresponding secondary antibodies conjugated
to horseradish peroxidase were purchased from GE Healthcare
(Orsay, France). Keratan sulfate (Mr 18000) from bovine cornea
was a generous gift of Prof. Karamanos (Patras, Greece) and chon-
droitin sulfate (Mr 22000) was obtained from Sigma (St-Quentin
Fallavier, France).
2.2. Cell culture
Murine B16F1 melanoma cells from ATCC (CRL-6323™) were
cultured in DMEM in standard conditions [9]. In all experiments,
cell viability was greater than 95%, as assessed by trypan blue
exclusion test.
2.3. Glycosaminoglycan (GAG) chain degradation
One microgram of recombinant decorin was incubated in reac-
tion buffer (40 mM Tris–HCl, 40 mM CH3COONa, pH 8.0) with
25 mU Chondroitinase ABC for 2 h at 37 C. The efﬁciency of GAG
degradation was analyzed by SDS–PAGE gel electrophoresis and
Western blot using anti-decorin antibody.2.4. Proteoglycans digestion assay
One microgram of proteoglycans or their core proteins was
incubated in reaction buffer (50 mM Tris–HCl, 0.15 M NaCl,
10 mM CaCl2, 0.05% Brij35, 0.02% NaN3, pH 7.5) with catalytic
domain of MMP-14 at 37 C for 17 h. Enzyme concentration varied
from 0.15 nM to 13.5 lM depending on the substrate/enzyme
ratio. In parallel, negative controls including lumican or decorin
were incubated alone in the assay buffer during the same time.
The cleaved products were analyzed by SDS–PAGE electrophoresis
and Western blot using anti-lumican and anti-decorin antibodies.
After digestion of these SLRP, the activity of MMP-14 in samples
was measured using ﬂuorogenic substrate as below.
To assess the collagen digestion with MMP-14 [29,30], 0.5 lg of
lumican were pre-incubated with 20 ng of the enzyme during 1 h
at 37 C in ultrapure water, followed by addition of 14 lg of colla-
gen. Then, incubation lasted for 6 h at 37 C. Enzymatic reaction
was stopped by boiling samples in Laemmli buffer supplemented
with EDTA (20 mM). Samples were subjected to SDS–PAGE (7.5%
acrylamide) under reduction, and stained with Coomassie blue
R-250.
2.5. MMP-14 activity assay
The MMP-14 activity was measured in 96-well plates using a
1 lM (unless indicated otherwise) ﬂuorogenic substrate: 5-FAM/
QXL™520 FRET peptide in the reaction buffer supplied in Senso-
Lyte 520 MMP-14 Assay Kit (AnaSpec, San Jose, USA) at excitation
and emission wavelengths of 490 and 520 nm, respectively. The
assays were carried out in triplicate at 37 C. Fluorescence was
measured with a spectroﬂuorometer (Mithras LB940, Berthold
Technologies, Thoiry, France).
To determine the effect of lumican and decorin on MMP-14
activity in vitro, B16F1 cells were incubated for 48 h with
1–100 nM lumican or decorin and cell lysates were then used for
measurements of MMP-14 activity. The activity of MMP-14 in
the samples was measured according to the protocol of the
supplier.
To determine the direct effect of SLRP proteins on MMP-14,
recombinant MMP-14 (5 nM) was pre-incubated at 37 C for
15 min or 17 h as indicated, before assay with lumican, its core
protein (2.5–75 nM), decorin, keratan sulfate or chondroitin sulfate
(75 nM each).
For kinetic enzyme inhibition studies, increasing concentrations
of substrate (0.01–1 lM) were added to a mixture of MMP-14
(5 nM) and lumican (1–50 nM). The measurement of the initial
velocity, as hydrolysis of the ﬂuorogenic substrate, was monitored
for 15 min with measurements taken every 3 min. Lineweaver–
Burk plot was used to determine the type of inhibition [31]. Esti-
mation of Ki value was obtained from the linear regression plot
of KMapp/VMAX as a function of the inhibitor (lumican) concentra-
tion [32]. Similar results were obtained from at least two indepen-
dent experiments.
2.6. Determination of the kinetic parameters using biosensor BIAcore
Surface plasmon resonance (SPR) analysis was performed using
a BIAcore T200 instrument (GE Healthcare Bio-Sciences AB, Upp-
sala, Sweden). The BIAcore sensor chip CM5, HBS [10 mM HEPES,
3.4 mM EDTA, 150 mM NaCl, and 0.05% surfactant P20 (pH 7.4)],
and the amine coupling kit were obtained from GE Healthcare
(Velizy-Villacoublay, France). The amine coupling kit was used to
activate the carboxymethylated dextran surface of the sensor chip.
Immobilization of the ligand was achieved via injection of MMP-14
(15 ll, 40 nM in 0.05 M sodium acetate buffer, pH 4.5, 5 ll/min) as
previously described [33]. Residual N-hydroxysuccinimide esters
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performed with a constant ﬂow of 10 ll/min at 25 C. Fifty micro-
liters of lumican (0.625–5 lM) in HBS were injected over the sur-
face for the association phase. The surface was regenerated with
25 ll of 1 mM NaOH (10 ll/min) followed by an extensive washing
of the system and by equilibration of the surface with HBS. To esti-
mate the increase of the signal from the detector, in resonance
units (RU) resulting from the non-speciﬁc effect of an analyte,
the protein on the bulk refractive index, the binding of protein to
a control surface with no immobilized ligand was also measured.
This non-speciﬁc signal was subtracted from the measured signal
for the interaction between MMP-14 and lumican. Association
and dissociation rate constants were determined by analyzing
the appropriate fragments of the sensorgram using BIAcore T200
Evaluation Software (GE Healthcare) and calculated from two inde-
pendent experiments.
2.7. Statistical analysis
Results were expressed as mean ± S.D. Statistical signiﬁcance
between groups was assessed by unpaired Student’s t-test. The
p value < 0.05 was considered statistically signiﬁcant.
3. Results and discussion
3.1. Lumican inhibits MMP-14 activity in a more efﬁcient way than
decorin
Lumican and decorin were shown to regulate MMP-14 expres-
sion in different types of cells [22,24]. To determine the effect of
these two SLRPs on the MMP-14 in melanoma cells, B16F1 cells
were incubated for 48 h with lumican or decorin followed by the
measurement of enzymatic activity. Lumican decreased MMP-14
activity in a dose-dependent manner (Fig. 1A). Similar inhibition
was obtained in previous studies using human mesenchymal stem
cells [25]. In B16F1 cell line, decorin did not impede the MMP-14
activity (Fig. 1B). In addition, previous study from our laboratory
showed that lumican-derived peptides were able to regulate the
MMP-14 expression in B16F1 cells [34]. These results suggest that
lumican, but not decorin, speciﬁcally decreases the MMP-14 activ-
ity in melanoma cells by interaction with the enzyme.
In dermis, lumican is found in different forms as core protein or
glycoprotein, due to different glycosylation proﬁles [2]. Therefore,
in our studies, two forms of lumican (core protein and glycopro-0 
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Fig. 1. Lumican decreases MMP-14 activity in B16F1 cells. The activity of MMP-14 in B16
as described in Section 2. MMP-14 activity was measured using ﬂuorimetric SensoLyte
from three independent experiments (⁄⁄p < 0.01, ⁄⁄⁄p < 0.001).tein) were used. Decorin was used in its native form only, since
the majority of decorin is secreted as a proteoglycan [35]. The
changes of enzymatic activity may be the consequence either of
the regulation of protein synthesis/maturation or of the effect of
the interaction between enzyme and its modulators, so we focused
on the direct inﬂuence of lumican on MMP-14. Lumican directly
inhibited, in a dose-dependent manner, the activity of MMP-14
as soon as 15 min after incubation with the enzyme (Fig. 2A).
The statistically signiﬁcant inhibition was obtained with 5 nM
lumican and 80% inhibition was obtained with 75 nM lumican. This
effect was not observed when 75 nM lumican core protein was
used. This result suggests that the glycosylation of lumican is nec-
essary for MMP-14 inhibition. In comparison, decorin only slightly
inhibited the MMP-14 activity after 15 min of incubation (Fig. 2A).
This partial inhibition of MMP-14 activity can be explained by a
competition of lumican and decorin with the ﬂuorogenic substrate
for the active site of the enzyme or a direct interaction with ﬂuo-
rogenic substrate.
To clarify whether the two SLRPs could serve as substrates for
MMP-14, as previously described [20,21], a cleavage assay was
performed. To obtain the steady state, lumican core protein was
incubated 17 h with MMP-14. Several protein fragments/products
of digestion could then be detected in both, 1:10 and 1:30 MMP-
14 to lumican core protein molar ratio (Fig. 2B), which conﬁrmed
the results obtained by others [21]. Conversely, when glycosylated
form of lumican was incubated 17 h with MMP-14, no protein frag-
ment was detected (Fig. 2B). The glycosylation is often cited to
induce a stabilizing effect upon proteins with respect to proteolysis
[36]. Apparently, the glycosylation of lumican protected its core
protein from degradation, probably by masking the MMP-14 cleav-
age sites. Moreover, no fragment of decorin was detected after
incubation of MMP-14 with recombinant molecule (Fig. 2C).
Because GAG chain could ‘‘mask’’ the cleavage site for MMP-14,
decorin was also incubated with MMP-14 after GAG chain degra-
dation. Our results show that native soluble decorin (glycosylated
or not) and native glycosylated form of lumican are not or are poor
substrates for MMP-14. Lumican core protein may serve as sub-
strate for MMP-14, whereas glycosylated formmay act as its inhib-
itor. To verify this hypothesis, MMP-14 activity was assessed after
17 h incubation with enzyme. After digestion of lumican core pro-
tein, only 50% of MMP-14 enzymatic activity remained in compar-
ison to control (Fig. 2D). These results suggest that lumican (or its
fragments produced during digestion) can strongly inhibit the
activity of MMP-14. During digestion with MMP-14, lumican orDecorin  
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could lead to changes in the conformation of MMP-14 and loss of
its activity. It will be of interest to determine which sequence from
lumican is responsible for this effect.
The presence of glycosylated form of lumican nearly totally
(98%) blocked MMP-14 activity. Moreover, this effect seems to
be speciﬁc for lumican, since, in the presence of glycosylated deco-
rin, MMP-14 still exhibited about 80% of its activity. Neither chon-
droitin sulfate, nor keratan sulfate inhibited MMP-14 activity
(Fig. 2E). These results indicate that the glycosylation of lumican
is necessary for complete inhibition of MMP-14 activity. On the
contrary, in comparison to lumican, decorin is an inefﬁcient or a
weak inhibitor of the enzyme.
3.2. Lumican directly binds to MMP-14 and inhibits its activity as a
competitive inhibitor
The proteolytic activity of MMPs involved in ECM degradation
and remodeling is precisely regulated by their endogenous protein
inhibitors, the tissue inhibitors of metalloproteinases (TIMPs).
TIMP-2, TIMP-3 and TIMP-4 are strong inhibitors of MMP-14,
whereas TIMP-1 has no signiﬁcant effect on MMP-14 function
[37]. To determine the type of inhibition of MMP-14 lumican,
kinetic studies were performed using catalytic form of enzyme.
Increasing concentrations of substrate (0.01–1 lM)were incubated
with a mixture of a constant concentration of MMP-14 (5 nM) and
various concentrations of lumican (1–50 nM). Kinetic studies using
Lineweaver–Burk plot indicated a competitive mechanism of inhi-
bition (Fig. 3A) with a Ki  60 nM (insert), suggesting a direct inter-
action of lumican with the catalytic site of the enzyme.
SPR binding assays were performed to conﬁrm the direct inter-
action of the catalytic domain of MMP-14 with lumican (Fig. 3B).
Lumican bound to the immobilized MMP-14 and formed a stable
complex. When lumican was injected at increasing concentrationsover MMP-14 to calculate rate constants and afﬁnity, the experi-
mental data were best ﬁtted to a 1:1 binding model with a calcu-
lated KD of 275.4 ± 16.12 nM. Such KD was consistent with those of
other MMP-14 inhibitors, since the KD value for its biological inhib-
itor TIMP-2 is 56 nM and for TIMP-1 is 1530 nM [33]. Therefore
MMP-14 may be considered as a new cell surface receptor for
lumican, since its binding afﬁnity to this metalloproteinase was
similar to its binding afﬁnity to the a2 integrin subunit
(KD  200 nM) [27].
Li and collaborators [21] demonstrated the degradation of lumi-
can by MMP-14 which was associated with the loss of its anti-
tumoral function. In their study, they used GST-tagged protein
which, as demonstrated by the SDS–PAGE migration, was not fully
glycosylated. On the contrary, their proteoglycan form of lumican
was not degraded to discrete peptides. In this work, we used two
different methods to demonstrate MMP-14-lumican interaction.
Firstly, an inhibition of enzymatic activity was observed using well
deﬁned enzyme/substrate system. Secondly, the binding assay sug-
gested a direct afﬁnity of lumican to MMP-14. In addition, our
results showed that the lumican glycosylation status may inﬂu-
ence on MMP-14 interaction. Our preliminary data (not shown)
suggest that a speciﬁc sequence of lumican LRR region ﬁts with
the catalytic pocket of the enzyme. It is well known that some
sequences of the LRR region have a weak homology between lumi-
can and decorin. This may explain why decorin is a very poor
inhibitor of MMP-14 in comparison to lumican. Further studies
are in progress to elucidate this question.
3.3. Lumican protects collagen against MMP-14 dependent
degradation
MMP-14 possesses collagenase and gelatinase activities [29].
Incubation of type I collagen with active form of MMP-14 resulted
in partial degradation of its a1 chain and almost total degradation
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4). When collagen was mixed with lumican without or with prein-
cubation before enzyme addition, at least partial inhibition of a2
chain and b1,2 dimer degradation was observed (Fig. 4, lanes 5
and 6). Moreover, no visual degradation of collagen was seen when
lumican was preincubated with MMP-14 prior to addition of colla-
gen (Fig. 4, lane 7). These results indicate that lumican is also able
to inhibit the MMP-14 activity towards collagen. Preincubation
between lumican and MMP-14 was more efﬁcient to protect colla-
gen from proteolysis. Indeed, this preincubation seems to lead to a
complex which decreases the collagenolytic activity of MMP-14.
Our studies show for the ﬁrst time that lumican, but not deco-
rin, is able to inhibit MMP-14 activity in melanoma cells. The
results indicate that a direct interaction between glycosylated form
of lumican and MMP-14 leads to a complete blocking of the activ-
ity of the enzyme. Moreover, MMP-14 can be considered as a new
lumican cell surface receptor. The binding of lumican to MMP-14
leads to the inhibition of its proteolytic activity.
MMPs have been shown to be key players in both ECM remod-
eling and cell migration during cancer metastasis. MMP-14, a
membrane-anchored MMP, is closely associated with these pro-
cesses [38]. MMP-14 expression is essential to confer to cancer
cells an ability to invade type I collagen matrix [39,40]. It plays
an important role in cell migration, not only by regulating the
activity or expression of downstreamMMPs, but also by processing
and activating migration-associated molecules including integrins,
collagens, cell surface proteoglycans, and other extracellular
4324 K. Pietraszek et al. / FEBS Letters 588 (2014) 4319–4324macromolecules, thus inﬂuencing a variety of intracellular signal-
ing pathways [41]. MMPs expression and activity in cells can be
also regulated by SLRPs [22–25]. For example, the overexpression
of decorin in endothelial cells, increases the mRNA level of
MMP-14 [22]. The inhibition of MMP-14 activity by lumican may
have important biological consequences such as protecting the
collagen ﬁbrils against the enzyme attack and contributing to
attenuation of MMP-14-dependent cancer cell migration.
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